Skip to content

Clinical study of cetuximab combined with capecitabine for maintenance of recurrent or metastatic head and neck squamous cell carcinoma

Clinical study of cetuximab combined with capecitabine for maintenance of recurrent or metastatic head and neck squamous cell carcinoma

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400087861
Enrollment
Unknown
Registered
2024-08-06
Start date
2024-09-01
Completion date
Unknown
Last updated
2024-08-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Squamous cell carcinoma of head and neck

Interventions

Sponsors

Xiyuan Hospital of CACMS
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Age = 18 years old and 40 mL/min(using Cockcroft-Gault formula): Female CrCl=(140- age)× Body weight (kg)× 0.85 / (72×Scr mg/dl) Male CrCl=(140- age)× Body weight (kg)× 1.00 / (72×Scr mg/dl) (6) AST/ALT=3 x ULN (7) Total bilirubin =1.5×ULN (except Gilbert syndrome)

Exclusion criteria

Exclusion criteria: 1. Patients with active brain or meningeal metastasis; 2. Patients with squamous cell carcinoma of unknown origin; 3. Patients with uncontrolled malignant tumors within the past 3 years; 4. Patients with a history of primary immunodeficiency or allogeneic organ transplantation; 5. Have untreated and/or uncontrolled cardiovascular disease, and/or symptomatic heart dysfunction (unstable angina pectoris, congestive heart failure, myocardial infarction within the past year or ventricular arrhythmia requiring medical treatment, history of second or third degree atrioventricular block). Patients with a history of major heart disease, even if controlled, must have >50% LVEF within 12 weeks prior to immunotherapy; 6. Patients with severe liver injury (total bilirubin > 3 ULN and any AST); 7. Physical and laboratory test results: a) Positive hepatitis B virus surface antigen (HBV sAg) or hepatitis C virus ribonucleic acid (HCV antibody), indicating acute or chronic infection. b) Known history of positive testing for human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS). c) Any Level 4 laboratory anomaly; 8. Allergy and adverse drug reactions: history of allergy to drug ingredients; A history of severe allergic reactions to any monoclonal antibody; 9. Active serious clinical infections, including active tuberculosis.

Design outcomes

Primary

MeasureTime frame
progression-free survival(PFS);

Secondary

MeasureTime frame
Objective remission rate (ORR);Disease control rate (DCR);overall survival (OS);

Countries

China

Contacts

Public ContactZhang Tong

Xiyuan Hospital of CACMS

ashtray7654@126.com+86 187 1004 7520

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026